There are currently 665 clinical trials in Milwaukee, Wisconsin looking for participants to engage in research studies. Trials are conducted at various facilities, including Medical College of Wisconsin, Childrens Hospital of Wisconsin, Aurora Saint Luke's Medical Center and Aurora Sinai Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Diagnosis of Fatty Liver with Outpatient Ultrasound
NCT03542578
Recruiting
This study will evaluate whether ultrasound performed during outpatient visit is effective in early diagnosis of fatty liver.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
02/19/2025
Locations: Froedtert Hospital, Milwaukee, Wisconsin
Conditions: Liver Steatoses
Register for Updates
Assessment of Fatty Liver with Thermo-acoustic Device
NCT04302051
Recruiting
The study will evaluate the accuracy of hepatic steatosis estimation by thermo-acoustic ultrasound with estimation by MRI-PDFF (Proton Density Fat Fraction) . It will also evaluate the sensitivity of this device in the diagnosis of fatty liver.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
02/19/2025
Locations: Froedtert Hospital, Milwaukee, Wisconsin
Conditions: NASH, NAFLD, Non-alcoholic Fatty Liver, Non-Alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis, Fatty Liver, Fatty Liver Disease
Register for Updates
Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
NCT05659381
Recruiting
Patients will be registered prior to, during or at the completion of neoadjuvant chemotherapy (Paclitaxel 175 mg/m2 IV over 3 hours and Carboplatin AUC 6 IV on Day 1 every 21 days for 3-4 cycles). Registered patients who progress during neoadjuvant chemotherapy will not be eligible for iCRS and will be removed from the study. Following completion of neoadjuvant chemotherapy, interval cytoreductive surgery (iCRS) will be performed in the usual fashion in both arms. Patients will be randomized at... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/18/2025
Locations: Froedtert Memorial Lutheran Hospital & Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Stage III Ovarian Cancer, Stage IV Ovarian Cancer, Stage III Primary Peritoneal Cancer, Stage IV Primary Peritoneal Cancer, Stage III Fallopian Tube Cancer, Stage IV Fallopian Tube Cancer
Register for Updates
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
NCT04186520
Recruiting
This is a Phase I/II, interventional, single-arm, open-label, treatment study designed to evaluate the safety and efficacy of Interleukin-7 and Interleukin-15 (IL-7/IL-15) manufactured chimeric antigen receptor (CAR)-20/19-T cells as well as the feasibility of a flexible manufacturing schema in adult patients with B cell malignancies that have failed prior therapies.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
02/17/2025
Locations: Medical College of Wisconsin and Froedtert Hospital, Milwaukee, Wisconsin
Conditions: Non Hodgkin Lymphoma (NHL), Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma, Marginal Zone Lymphoma, Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B-cell Lymphoma (PMBCL), Central Nervous System Lymphoma
Register for Updates
LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
NCT05990465
Recruiting
This is a phase I, interventional, single arm, open label, treatment study designed to evaluate the safety and efficacy of LV20.19 CAR -T cells with pirtobrutinib bridging and maintenance in adult patients with B cell malignancies that have failed prior therapies.
Gender:
ALL
Ages:
Between 18 years and 81 years
Trial Updated:
02/17/2025
Locations: Froedtert & the Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Burkitt Lymphoma
Register for Updates
Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma
NCT06048484
Recruiting
The purpose of this study is to combine standard radiation therapy with drugs that encourages the body's immune system against cancer cells and simultaneously adding drugs which also target the pathway that the tumor uses to evade the immune system (CD73 and A2a/b). The study hopes that these drugs will work in concert with radiation therapy to kill cancer cells. The specific goal of this study is to ensure that treatment with zimberelimab and stereotactic body radiation therapy (SBRT) alone or... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/11/2025
Locations: Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Pancreatic Ductal Adenocarcinoma
Register for Updates
Fatigability of Lower Limb Muscle in Older Adults: Protective Effects of Strength Training Exercise in Old Men and Women
NCT03888040
Recruiting
The proposed studies will assess 1) the mechanisms for the age-related increase in fatigability during dynamic exercise (Aims 1 and 2) and 2) the effectiveness of high-velocity resistance training coupled with blood flow restriction (BFR) in improving muscle power output and fatigability in older adults (Aim 3). The first two aims are cross-sectional studies comparing young (18-35 years old) and older adults (≥60 yrs old) to test our central hypothesis that the greater accumulation of metabolite... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
02/08/2025
Locations: Marquette University, Milwaukee, Wisconsin
Conditions: Aging
Register for Updates
Post-Market Clinical Investigation Plan - Collagen Dura Membranes (DM & DMO)
NCT06822920
Recruiting
Monitoring the Use of Collagen Dura Membrane in the Post-market phase
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/07/2025
Locations: Medical Collagen of Wisconsin, Milwaukee, Wisconsin
Conditions: Repair of Dura Mater
Register for Updates
Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed And/or Refractory Multiple Myeloma
NCT04835129
Recruiting
This is a multicenter, open-label phase II study in subjects with relapsed and/or refractory multiple myeloma with at least two prior lines of therapy. The main study consists of three phases: a 28-day screening phase, treatment phase that consists of 28-day cycles of isatuximab with elotuzumab, pomalidomide, and dexamethasone and a follow-up phase.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/05/2025
Locations: Froedtert Hospital & the Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Multiple Myeloma
Register for Updates
PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III
NCT05934487
Recruiting
This is a prospective, multi-center, open label, randomized control clinical trial evaluating the safety and efficacy of the Cordella™ Pulmonary Artery Sensor System in NYHA Class II-III Heart Failure Patients (PROACTIVE-HF-2 Trial). The study contains of 5 arms: NYHA II Cohort - To demonstrate safety and efficacy of the Cordella PA Sensor System in NYHA Class II HF patients, where patients have daily access to PAP data. * Treatment Arm (Group 1) * Active Control Arm (Group 2) * Crossover Arm... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/05/2025
Locations: Advocate Aurora St. Luke's, Milwaukee, Wisconsin
Conditions: Heart Failure NYHA Class II, Heart Failure NYHA Class III, Heart Failure
Register for Updates
Iadademstat with Hypomethylating Agent in Patients with Myelodysplastic Syndrome
NCT06502145
Recruiting
This is a phase I study with a primary objective of determining the recommended phase II dose of iadademstat with azacitidine in adult subjects with myelodysplastic syndrome (MDS).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/05/2025
Locations: Froedtert Hospital & the Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Myelodysplastic Syndromes
Register for Updates
Gene Therapy Trial for Platelet Derived Factor VIII Production in Hemophilia a
NCT03818763
Recruiting
This is a Phase I study. This research study is being conducted to find new ways to treat severe hemophilia A. This study is a gene therapy study. Gene therapy is an experimental way to introduce, into a person's cells, specific genetic material. A gene can be delivered/introduced into a cell using a carrier known as a "vector." In this study, a virus (lentivirus), the "vector", is used to introduce or deliver a gene that creates and stores a protein Factor VIII (FVIII) in your platelets. These... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
02/04/2025
Locations: Froedtert Hospital and the Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Hemophilia A
Register for Updates